FDMT

On August 13, 2026, the company reported a Q2 2026 loss per share of ($1.04), missing consensus estimates, and a widened net loss of $72.9 million, contributing to a 5% stock price loss. Clinical trial advancements include 4DMT announcing the advancement of 4D-150 into Phase 3 for DME, reporting positive 2-year data from the Phase 1/2 PRISM trial for 4D-150 in wet AMD, receiving Regenerative Medicine Advanced Therapy (RMAT) designation for 4D-150 for DME, and gaining regulatory approval for an Investigational New Drug (IND) application for 4D-175. CEO David Kirn sold 58,333 shares on October 5, 2026, part of a broader pattern of insider selling over the past year with no reported insider buys. As of early October 2026, FDMT stock fell by -5.59% in the previous week and -7.69% in the last month, but showed a 38.28% increase over the last year.